Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Payables (2018 - 2025)

Bicycle Therapeutics' Payables history spans 8 years, with the latest figure at $9.7 million for Q4 2025.

  • For Q4 2025, Payables fell 38.78% year-over-year to $9.7 million; the TTM value through Dec 2025 reached $9.7 million, down 38.78%, while the annual FY2025 figure was $9.7 million, 38.78% down from the prior year.
  • Payables reached $9.7 million in Q4 2025 per BCYC's latest filing, down from $12.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $18.3 million in Q2 2025 to a low of $996000.0 in Q1 2021.
  • Average Payables over 5 years is $7.4 million, with a median of $6.8 million recorded in 2022.
  • Peak YoY movement for Payables: crashed 77.54% in 2021, then skyrocketed 301.51% in 2022.
  • A 5-year view of Payables shows it stood at $2.7 million in 2021, then skyrocketed by 137.85% to $6.5 million in 2022, then skyrocketed by 101.64% to $13.0 million in 2023, then increased by 21.02% to $15.8 million in 2024, then plummeted by 38.78% to $9.7 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Payables are $9.7 million (Q4 2025), $12.7 million (Q3 2025), and $18.3 million (Q2 2025).